Related by context. All words. (Click for frequent words.) 74 chronic myeloid leukemia Ph 73 Ph + chronic myeloid 70 leukemia CML 68 Ph + acute lymphoblastic 67 acute lymphoblastic leukemia Ph 61 chronic myeloid 60 Ph + 60 Ph chromosome 59 diagnosed Ph + 59 refractory CML 58 CAP accredited CLIA 58 tests miRview TM 57 humanized therapeutic 57 authority Gurian Sherman 57 acute myeloid 56 RUNS Rollins 56 Chronic myeloid leukemia 56 lymphomas leukemias 56 BCR ABL tyrosine kinase 56 Gleevec resistant 56 Bosutinib 56 Rosetta Genomics CLIA certified 56 phase Ph + 56 Lippincott Raven 56 MELAS 56 pharmacogenomic translational research 56 related CMV Retinitis 56 thrombopoietin TPO natural 56 refractory chronic lymphocytic 56 tests miRview ™ 55 5 HT2A serotonin 55 K ras mutations 55 dasatinib Sprycel 55 BRAF V#E 55 Shows Efficacy 55 imatinib resistance 55 Submits Response 55 RQ PCR 55 kidney urologic 55 Philadelphia Chromosome Positive 55 mutated K ras 55 HLA DR4 immune 55 urate oxidase 55 hypereosinophilic syndrome 55 imatinib resistant 55 CLIA certified lab 55 fibrosarcoma 55 Situ Hybridization 55 CML CP 55 Human Leukocyte Antigen 55 plasmacytoid 55 Ribavirin causes 55 adrenocortical cancer 55 Vitrasert R 54 5 HT1A receptor 54 biliary tract cancer 54 Systemic lupus erythematosus 54 Improves Outcomes 54 Initiate Clinical Trial 54 Bayer HealthCare Onyx Pharmaceuticals 54 nilotinib Tasigna 54 metastatic malignant 54 HCV RNA polymerase 54 FSH follicle stimulating 54 Bcr Abl T#I mutation 54 essential thrombocythemia ET 54 potent inducer 54 myelodysplastic myeloproliferative diseases 54 Nilotinib 54 BRCA1 BRCA2 54 papillary renal cell carcinoma 54 Leukemias 54 refractory chronic myeloid 54 chronic myeloid leukemia CML 54 glutamic acid decarboxylase 54 CYP#A# CYP#D# 54 Kit CD# positive 54 Upregulation 54 Imatinib mesylate 54 approved incretin mimetic 54 designated Restanza 54 Topoisomerase II 54 Predict Response 54 gag pol 54 DOUBLES Utley 54 dihydrofolate reductase 54 Selective serotonin reuptake inhibitors 53 Patients Treated With 53 K ras gene 53 ALB # 53 chronic granulomatous disease 53 radioimmunotherapeutic agent 53 relapsed MM 53 secretagogues 53 Respiratory Virus 53 PEGylated anti 53 Achieves Primary Endpoint 53 fusion enhancers 53 LAB CGRP 53 CYT# potent vascular disrupting 53 HMGCR 53 hematopoietic cancers 53 steroidogenic 53 squamous miRview TM 53 dyskeratosis congenita 53 treat chronic sinusitis 53 novel emulsion formulation 53 sitaxsentan 53 Presents Positive 53 normal karyotype 53 haematologic 53 Gamunex C 53 inhibiting telomerase 53 inhibitor COX 53 Initiates Enrollment 53 subependymal giant cell 53 gastrointestinal stromal tumors GISTs 53 inhibit oxidative stress 53 GSTT1 53 PENNVAX ™ B 53 dyslipidemia abnormal 53 Dasatinib 53 human IgG1 monoclonal 53 ® imatinib mesylate 53 hepatic lipase 53 Chronic Myelogenous Leukemia 53 Maralyn Lois Polak 53 Ph + CML 53 selective modulator 53 hematological cancers notably 53 Initiates Phase II 53 survivin expression 53 pharmacologically active isomer 53 Refractory Hodgkin Lymphoma 53 Sodium oxybate 53 Shows Promise Against 53 Romiplostim 53 Chronic lymphocytic leukemia CLL 53 Temsirolimus 53 bronchoalveolar lavage BAL 53 Files IND 53 covalently bound 53 Combination REOLYSIN R 53 Undesirable alterations 53 transthyretin TTR 53 osteoprotegerin 53 GRK5 53 neurons degenerate 53 Known hypersensitivity 53 Papillary 53 relapsed acute lymphoblastic 53 AGTR1 53 quetiapine Seroquel 53 Pathway Inhibitor 53 Tie2 53 peri implant 52 Valproic acid 52 prognostic biomarker 52 Ph + CP 52 Successfully Treated 52 enzymatically activated within 52 Poorly Controlled 52 Tasigna prolongs 52 SPRYCEL ® 52 Associated Adipose Redistribution 52 Estrogen receptor positive 52 chimeric monoclonal antibody 52 lymphoid cancers 52 dyslipidemia hypertension diabetes 52 DNA demethylating agent 52 potentially hepatotoxic 52 Lymphocytic 52 addition HANABI automated 52 anaplastic lymphoma kinase ALK 52 Maven Semantic 52 Postmenopausal hormone therapy 52 idiopathic PAH 52 tryptase 52 Tyrosine Kinase Inhibitors 52 Pegloticase 52 LymphoStat B belimumab 52 selectively inhibited 52 lymphoid malignancies 52 non mutated KRAS 52 Arrhythmogenic 52 Hypertrophy 52 Isavuconazole 52 catechol O methyltransferase COMT 52 Hodgkin lymphoma HL 52 Node Positive 52 mda 7 52 Targeted Diagnostics 52 CYP#A# isoenzyme 52 polycythemia vera essential thrombocythemia 52 zoledronic acid Reclast 52 folate analogue metabolic 52 Significantly Improves 52 diagnosed chronic myeloid 52 LHRH receptor positive 52 recovery CRp 52 EGFR mutation positive 52 #-# Full Text 52 glucokinase 52 Investigational Compound 52 Systemic Delivery 52 Myelofibrosis 52 PIK3CA 52 receptor inhibiting monoclonal 52 SLITRK1 52 selective reuptake inhibitors 52 Polyneuropathy 52 Plaquenil 52 oral squamous cell 52 Hypercholesterolemia 52 R abatacept 52 receiving XGEVA 52 treat secondary hyperparathyroidism 52 Plicera TM 52 impaired glucose metabolism 52 Cytogenetic 52 Mutational 52 murine leukemia virus 52 potently inhibit 52 HER2 amplified 52 selective phosphodiesterase 52 PET tracer 52 Shows Promising 52 EliA 52 familial hypercholesterolemia FH 52 gastric carcinoma 52 Fibroblast 52 containing abacavir 52 dopamine D2 52 lymphoid blast 52 HPV vaccine GlaxoSmithKline Cervarix 52 Degarelix 52 MLH1 52 demonstrated antitumor activity 52 Glycosylation 52 Callisto initiated 52 Letairis ambrisentan 52 Presents Preclinical 52 inhibin B 52 thalassemia sickle cell 52 Granted Orphan Drug 52 catechol O methyltransferase 52 hyaluronidase enzyme 52 Chronic lymphocytic leukemia 52 hypermethylated 52 diagnostic biomarker 52 Warfarin Coumadin 52 microsomal triglyceride transfer 52 ER CHOP 52 Meets Primary Endpoint 52 Progressive Multifocal Leukoencephalopathy 52 myeloproliferative neoplasms MPNs 52 chronic myeloid leukemia 52 induced anemia 52 Synvisc ONE 52 AAG geldanamycin analog 52 interferon inducible 52 kappa B 52 autologous cellular immunotherapy 52 Transgenomic Pharmacogenomics Services 52 Elevated serum 52 Vidaza R 52 ornithine decarboxylase 52 mitogen activated protein 52 Completes Patient Enrollment 52 plasmid DNA encoding 52 Myeloid 52 Naive Patients 52 essential thrombocythemia 52 upregulates 52 ADVERSE EVENTS 52 directed radiotherapeutic antibody 52 reduce serum phosphate 52 severely active polyarticular 52 pregabalin Lyrica 51 pretreatment serum 51 multifactorial disease 51 bronchoalveolar 51 psoriasis Crohn disease 51 Sirtex SIR Spheres microspheres 51 somatostatin analog 51 infused intravenously 51 nephropathic cystinosis cystinosis 51 cytogenic 51 Grants Orphan Drug 51 CYP #D# 51 myelofibrosis polycythemia vera 51 Monoclonal antibody 51 follicular Non Hodgkin 51 evaluating mipomersen 51 Riluzole 51 HIV reverse transcriptase 51 affective psychosis 51 Simon Gagne foiled 51 Helps Relieve 51 selective A2A adenosine receptor 51 Adenoviral 51 Mg Uk 51 lung ovary 51 neuropeptide Y NPY 51 hormone receptor negative 51 evaluating ambrisentan 51 Oshkosh Wis. Peoria Ill. 51 Omacetaxine 51 diagnosed glioblastoma 51 thymosin beta 4 51 R lenalidomide 51 PI3K signaling 51 HIF 1α 51 Tyrosine Kinase Inhibitor 51 MYH9 gene 51 Receives Orphan Drug Designation 51 Fingolimod 51 chronic eosinophilic leukemia 51 recombinant PSMA vaccine 51 Osteogenesis imperfecta 51 Vaclav Prospal Braydon Coburn 51 HER2 expression 51 platelet dysfunction 51 #:#-#,# CrossRef Medline [002] 51 Streptococcus agalactiae 51 Sudhir Agrawal D.Phil 51 proprietary radiolabeled monoclonal 51 monogenic 51 receptor tyrosine kinase inhibitor 51 plus fludarabine 51 synthetic peptide containing 51 EGFR TKI 51 monoclonal anti 51 potent suppressor 51 lymphoma myeloma 51 Triapine 51 CD#c 51 HLA DR4 51 squamous cell lung cancer 51 Antisocial personality 51 Familial Hypercholesterolemia 51 refractory cutaneous T 51 taxane chemotherapy administered 51 HepDirect prodrug 51 factor TNF receptor 51 leiomyomas 51 mesylate tablets approved 51 Kinoid 51 Estrogen receptor 51 Initiate Phase 51 Hematologic 51 Dementia Related Psychosis 51 Clinical Trials Review 51 unresectable inoperable 51 completely resected 51 Soft Tissue Sarcoma 51 gastrointestinal stromal tumors 51 Peginterferon alfa 2b 51 ® lenalidomide 51 Submits Biologics License Application 51 CYP#A# substrate 51 dermatofibrosarcoma protuberans 51 cyclase 51 LRP5 51 R Saizen R 51 glucocorticoid induced 51 Darinaparsin 51 number NCT# ClinicalTrials.gov 51 Pharmacokinetics PK 51 Initiates Phase III 51 Osteopontin 51 inhibits VEGF 51 opioid naive 51 includes ecallantide recombinant 51 NS5B polymerase 51 Bon Jovi Stevie Wonder 51 neuro developmental disorders 51 TOP2A 51 neuropathologic 51 Pittsburgh Colby Amstrong 51 chronic myelogenous leukemia CML 51 calcium calmodulin dependent 51 Prolongs Survival 51 treat atrial flutter 51 6 phosphate dehydrogenase 51 HUMIRA resembles 51 inverse agonist 51 polyglutamate 51 Evoltra ® 51 Cerezyme treats rare 51 Chronic Lymphocytic Leukemia CLL 51 gets USFDA nod 51 Vidaza ® 51 mitoxantrone chemotherapy 51 Protease Inhibitor 51 Submits IND 51 mitogen activated protein kinases 51 cutaneous T 51 cisplatin resistant 51 investigator Donna Tartaglino 51 Parathyroid hormone 51 syndrome gastroesophageal reflux 51 antisense inhibitors 51 Bucindolol 51 acute mania 51 metastatic colorectal carcinoma 51 Drug Shows Promise 51 rapamycin kinase 51 detect amyloid plaque 51 Metabolites 51 Acute Liver Failure 51 INSPIRE Trial Phase III 51 Microalbuminuria 51 severe malignant osteopetrosis 51 Orally administered 51 Myelodysplastic Syndrome MDS 51 Pathogenesis 51 Chronic Myelogenous Leukemia CML 51 Atypical Hemolytic Uremic Syndrome 51 vitro pharmacology 51 non squamous histology 51 selectively binds 51 aminotransferase 51 refractory acute myeloid 51 CFTR gene mutations 51 please visit http:/www.avastin.com 51 4 PDE4 enzyme 51 Glucocorticoid 51 Bafetinib 51 astemizole 51 Erythropoiesis Stimulating Agents ESAs 51 TNF Blockers 51 echocardiographic parameters 51 banned Darvon Darvocet 51 relapsed refractory 51 variant rs# 51 R vitespen 51 ActA 51 generation purine nucleoside 51 antiangiogenic agent 51 TO AVOID PREGNANCY WHILE 51 oral picoplatin 51 metastatic colorectal 51 decompensated liver disease 51 endocrinologic 51 BCR ABL inhibitor 51 alefacept 51 CD# CD# 51 warfarin erythromycin 51 norepinephrine reuptake inhibitor SNRI 51 nicotinamide adenine dinucleotide 51 raloxifene Evista 51 recurrent metastatic 51 DAT1 51 gamma glutamyl 51 Immunoglobulin E 51 fat malabsorption 51 relapsed mantle 51 TEL AML1 51 Hair follicle 51 Angiotensin Converting Enzyme 51 B Cell Lymphoma 51 Previously Treated 51 Histological 51 non porcine pancreatic 51 cytokine refractory 51 Hsp# Inhibitor 51 cardiac repolarization 51 Phase 2b Clinical Trial 51 Renal Artery 50 DP VPA 50 Janus kinase 50 albiglutide 50 autosomal recessive disorder 50 PLX STROKE targeting 50 granulosa cell 50 NCCN Updates 50 carmustine 50 gamma secretase activating 50 atypical hemolytic uremic syndrome 50 Sipuleucel T 50 abnormal methylation 50 Silodosin 50 aplastic anemia AA 50 de novo AML 50 Treg cell 50 #beta HSD1 50 palonosetron hydrochloride Injection Dacogen 50 Acute Coronary 50 protein tyrosine phosphatase 1B 50 intraepithelial neoplasia 50 Playoff Game Summary 50 GSTP1 50 aggressive systemic mastocytosis 50 RezularTM 50 leukaemias 50 chronic idiopathic thrombocytopenic purpura 50 5 lipoxygenase inhibitor 50 myeloproliferative 50 substantially excreted 50 KRAS BRAF 50 Begins Dosing 50 Cancer Incidence Mortality 50 bronchioloalveolar carcinoma 50 hemagglutinin H 50 transgenic mouse models 50 GPI anchored 50 Successfully Completes Phase 50 human leukocyte antigen HLA 50 lactate dehydrogenase LDH 50 CINQUIL 50 vapreotide acetate 50 IMPDH inhibitor 50 gastrointestinal stromal tumor 50 BRAF V#E mutation 50 Atomoxetine 50 gemifloxacin mesylate tablets fluoroquinolone 50 myeloid metaplasia 50 BioSante Pharmaceuticals Announces 50 rheumatoid arthritis psoriatic arthritis 50 Vertex hepatitis C 50 post transplant lymphoproliferative 50 Improves Survival 50 protein secreted 50 Her2/neu 50 Am J Clin 50 Cutaneous T 50 NIDDM 50 accumulate preferentially 50 improve impulse conduction 50 cortisol synthesis 50 ALK inhibitors 50 Quinamed R 50 index assay IVDMIA 50 leukemia AML 50 MCSP respectively 50 Inflammatory Arthritis 50 soluble TNF receptor 50 ENPP1 50 asthma rheumatoid arthritis 50 candidates Azedra TM 50 response CCyR 50 Acute Intermittent Porphyria 50 discontinued Viread 50 included exfoliative dermatitis 50 COMPELLENT TECHNOLOGIES 50 refractory colorectal cancer 50 BRAF gene mutations 50 Tasigna nilotinib 50 nonmelanoma 50 serotonin uptake 50 Tumor Cell 50 Factor Receptor 50 syngeneic 50 2A receptor agonist 50 histone deacetylation 50 PDGFRA 50 paraoxonase 50 Deforolimus 50 imatinib Gleevec ® 50 disease juvenile nephronophthisis 50 PROVENGE ® 50 5 lipoxygenase 50 thyroid carcinoma 50 cyclophosphamide doxorubicin vincristine 50 metastatic carcinoma 50 TP# gene 50 dimeglumine 50 malignant astrocytoma 50 Tyrosine kinases 50 Thimerosal preservative 50 plasmid encoding 50 treating psychiatric disorders 50 chemistry microbiology immunology 50 transplanted embryonic 50 receptor blocker 50 osteosarcomas 50 oropharyngeal candidiasis OPC 50 enzyme metabolizes 50 Humanized Anti 50 Inhaled nitric oxide 50 J Nutr 50 pancreas esophagus 50 non nucleoside inhibitor 50 precancerous prostate 50 induced phosphorylation 50 Behçet disease 50 1 diabetes T1D 50 peptide receptor 50 alpha#beta# integrin 50 Bacteremia 50 Vaxfectin formulated 50 Forodesine HCl 50 Tesmilifene 50 Parathyroid 50 Ziprasidone 50 anaplastic astrocytoma 50 hyperinsulinism 50 transthyretin amyloidosis 50 Pancreatic insufficiency 50 thetreatment 50 ZOLINZA 50 benign prostatic hypertrophy BPH 50 phosphoinositide 50 inborn errors 50 endometrial breast 50 daily subcutaneous injections 50 Lymphoid 50 lysosomal storage disease 50 pathophysiological effects 50 viral protease 50 LPLD 50 gastrointestinal stromal tumor GIST 50 rALLy 50 NATIONAL LGE 50 Diamyd r 50 Generalized Anxiety Disorder 50 SETDB1 50 HLA DR2 50 Lipodystrophy 50 diseases Cerezyme 50 Bendamustine 50 myeloperoxidase 50 InNexus Biotechnology Announces 50 alpha antagonist 50 PARP Inhibitor 50 NMIBC 50 metalloproteinase 50 Levoleucovorin 50 homozygous FH 50 Germ Cell 50 Aeolus Pharmaceuticals Announces 50 Mouse Models 50 constitutively expressed 50 Accessed #/#/# [001] 50 cladribine Cladribine Tablets 50 myeloid 50 hormone receptor status 50 Relapsed Refractory 50 cytogenetic responses 50 tumor histology 50 rheumatoid arthritis inflammatory bowel 50 phenothiazines 50 bone marrow reticulin deposition 50 ChronVac C 50 Arranon 50 ERalpha 50 Parnate 50 cell carcinoma RCC 50 pathological hallmark 50 myopathies 50 repeat paracentesis 50 DIFICID ™ 50 Treatment Naive Patients 50 Adrenergic 50 cromolyn sodium 50 retinoblastoma Rb 50 ABL1 50 Estrogen Receptor 50 leukotriene receptor antagonist 50 refractory indolent non 50 By Suria Rina 50 Retisert R 50 myeloid lineage 50 severe oral mucositis 50 KRAS wild 50 Clusterin 50 nanofiltered plasma derived 50 downregulates 50 Pa. SP# 50 Revascor ™ 50 LRAT 50 Avoid jalapenos 50 selective agonist 50 TNF Tumor Necrosis Factor 50 NKX#.# 50 VEGFR2 inhibitor 50 Vaccine Adjuvant 50 Alkaline phosphatase 50 albiglutide currently 50 Reveals Positive 50 Immunosuppressive 50 miconazole Lauriad ® 50 patientswith 50 Elestrin ® 50 hepatic enzyme 50 Nonalcoholic fatty liver 50 histological subtype 50 epithelial tumors 50 Shelmire aves 50 immunotoxin 50 Li Fraumeni syndrome 50 thromboembolisms 50 Lupus Nephritis 50 Chlamydia gonorrhea 50 Demonstrates Significant 50 FUSILEV enhances 50 HepG2 50 Initiates Clinical Trial 50 Peripheral Arterial 50 Nucleoside 50 Kahalalide F 50 Campath alemtuzumab 50 adenomatous polyposis coli 50 dasatinib Sprycel ® 50 Diffuse Large B 50 Cathepsin B 50 peptidic compound 50 Hyperlipidemia 50 stimulated insulin secretion 50 SNP rs# [001] 50 JAK2 V#F 50 TLR7 agonist 50 5 lipoxygenase activating 50 Complicated Skin 50 Submits NDA 50 trial evaluating PRX# 50 thalidomide Thalomid 50 VKORC1 50 multiple sclerosis irritable bowel 50 macrophage inflammatory 50 ductal adenocarcinoma 50 Test Detects 50 LH FSH 50 Adenomas 50 Immunohistochemical 50 Crofelemer budesonide foam 50 onset idiopathic hypogonadism 50 COPEGUS therapy 50 Initiates Phase 2b 50 Demonstrates Positive 50 Subtypes 50 topical gel formulation 50 Teriflunomide 50 tumor suppressor PTEN 50 tumors GIST 50 Transdermal Patch 50 multipotent adult 50 Systemic Juvenile Idiopathic 50 methyl CpG binding 50 surgically resected 50 Personalized Immunotherapy 50 finasteride Proscar 50 basal cell carcinoma squamous 50 Juvenile Idiopathic Arthritis 50 Cariprazine 50 tryptophan hydroxylase 50 humanized interleukin 6 50 inflammatory PDE 50 atrophic vaginitis 50 leukemia CLL 50 adrenocortical carcinoma 50 MSCRAMM ® 50 platform HDL Mimetic 50 DG# compounds targeting 50 Nation Spending Habits 50 Jose Contreras outpitched 50 1beta 50 pediatric acute lymphoblastic 50 endocrine hormones 50 Alagille syndrome 50 Drug Resistant 49 peroxisomal 49 serotonin norepinephrine 49 Interferon Beta 49 Author Affiliations 49 riboflavin vitamin B2 49 T#I [002] 49 Plavix clopidogrel bisulfate 49 hydroxylase 49 nasal aerosol 49 promotes calcium absorption 49 Gleevec imatinib mesylate 49 Mesenchymal 49 dual endothelin receptor antagonist 49 Peptide YY 49 OMP #R# 49 HLA DQ2 49 lipoprotein lipase LPL 49 TTR amyloidosis 49 Roche MabThera 49 complete cytogenetic response 49 anaplastic astrocytoma AA 49 ovarian pancreatic 49 hMG 49 plasminogen activator 49 human chorionic gonadotropin hCG 49 Castration Resistant Prostate Cancer 49 topoisomerase II inhibitor 49 humanised monoclonal antibody 49 III EGFRvIII 49 Author Affiliation Department 49 Prodarsan R 49 PIB PET 49 Globocan 49 liver steatosis 49 transfusion syndrome 49 weekly subcutaneous injections 49 mediated inhibition 49 advanced fludarabine refractory 49 peptibody 49 heFH 49 potent antiproliferative 49 COL#A# 49 #-#-# Markus Naslund 49 antithyroid 49 Human cl 49 SensoLyte 49 potent topoisomerase II 49 Adiposity 49 acadesine 49 Reduces Mortality 49 Discoveries Tomorrow 49 antiapoptotic 49 bronchial hyperresponsiveness 49 non resectable metastatic 49 mineralocorticoid 49 motilin 49 Reginal Simon 49 decarboxylase 49 plasminogen activator inhibitor 49 highly purified pasteurized 49 ovarian endometrial 49 microtubule associated 49 Epratuzumab 49 pancreatic lung 49 Regenerative Cell 49 Duluth Minn. Superior 49 Annamycin 49 Risperidone Oral Solution 49 Systemic lupus erythematosus SLE 49 imatinib therapy 49 patients receiving myelosuppressive 49 vitamin B# folic acid 49 Antitumor Activity 49 previously untreated follicular 49 PCNSL 49 By MATT GELB 49 attach auristatin 49 cytokines chemokines 49 Darroll Powe Scott Hartnell 49 retinoic acid receptor 49 squamous miRview ™ mets 49 Submits Supplemental 49 5alpha reductase 49 hemagglutinin gene 49 prostate carcinoma 49 Unfavorable matchup 49 gastric adenocarcinoma 49 exocrine 49 nonnucleoside reverse transcriptase inhibitors 49 Zeldox 49 Anthrax Toxin 49 endocrine metabolic 49 bronchoalveolar lavage fluid 49 Generalized Anxiety Disorder GAD 49 chromosome #q#.# deletion 49 Gastrointestinal Stromal Tumors 49 Talabostat 49 Interferon gamma 49 idiopathic membranous nephropathy 49 Histologic 49 NS5B 49 reverse transcriptase inhibitors 49 refractory Hodgkin 49 hypercholesterolemia liver 49 initiated Phase Ib 49 fine needle aspirate 49 deep venous thromboses 49 autoantibody positive 49 SEER registries 49 patients coinfected 49 tensin homolog 49 CCyR 49 ON MARCH #TH 49 Western blotting 49 HIV treatments Reyataz 49 Alzheimer's linked 49 Acute myelogenous leukemia 49 LDL cholesterol HDL cholesterol 49 3TC lamivudine 49 mutated BRCA 49 Aaron Fultz lhp 49 Acute myeloid leukemia 49 c KIT 49 approved CLIA waived 49 completed postdoctoral fellowship 49 Thorough cooking kills 49 Glatiramer acetate 49 CCR5 delta# 49 rheumatoid factor 49 Colon polyps 49 Symptom severity 49 granted Orphan Drug 49 QNEXA ® 49 Therapeutic Efficacy 49 beta. 49 corticotropin injection 49 HER2 HER2 49 unresectable tumors 49 Treanda bendamustine 49 MTHFD1L 49 radiosensitivity 49 recessive dystrophic epidermolysis bullosa 49 hepatoma 49 anaphylactic reactions bronchospasm 49 Cell Proliferation 49 cryopyrin associated periodic 49 mitoxantrone plus 49 concomitant plasma glucose 49 Cancer Institute UPCI 49 Apolipoprotein B 49 tubulin inhibitor 49 anterior pituitary 49 Vidaza azacitidine 49 AZT 3TC 49 Successfully Treats 49 deoxy 49 samalizumab 49 monoclonal antibody conjugated 49 Detroit Duluth Minn 49 SOD2 gene 49 succinate dehydrogenase 49 Commonly prescribed 49 stage IIIb IV 49 neurokinin 1 49 NPM1 gene 49 Breda Netherlands 49 Genentech sanofi aventis 49 Basal Cell 49 Vincristine 49 inhibit VEGF 49 minimally symptomatic 49 tyrosine hydroxylase 49 revascularized 49 Zavesca r 49 Zileuton 49 cloned primate 49 Advanced Melanoma 49 oesophageal adenocarcinoma 49 alpha1 antitrypsin deficiency 49 chemically modify 49 Multiple Ascending Dose 49 chemically alters 49 Single nucleotide polymorphisms 49 immune thrombocytopenic purpura 49 vivo toxicology 49 D BP# 49 Fragile X mental retardation 49 vitro diagnostic multivariate 49 Phenylketonuria 49 intranasal formulation 49 esophageal ulcers 49 Haptoglobin 49 Crizotinib 49 Fast Track Status 49 polyarticular 49 Mg Usa 49 mouse mammary 49 arachidonic 49 mTOR mammalian target 49 ® nilotinib 49 biochemical abnormalities 49 Genes Discovered 49 invasive lobular 49 topically administered 49 arachidonic acid AA 49 MCyR 49 apo E 49 promoter methylation 49 glucocerebroside primarily 49 Receives Positive Opinion 49 #:#-# [023] 49 ug dose 49 norepinephrine reuptake inhibitor 49 management biostatistical analysis 49 Pfizer Camptosar 49 defeated Enrique Ornelas 49 Emtriva Viread 49 transarterial 49 KV Pharmaceutical NYSE KVa 49 cell adhesion molecule 49 DNA hypermethylation 49 ACR# ACR# 49 polycythemia vera PV 49 #:#-#,# CrossRef Medline [001] 49 Keiwan Ratliff clinched 49 Acute lymphoblastic leukemia 49 novel antimitotic agent 49 Clofarabine 49 phthalate syndrome 49 metastatic gastric 49 MTHFR 49 leptin deficiency 49 complete cytogenetic 49 misregulated 49 mesangial 49 ERBB2 49 Denufosol